Skip to main content

Test-retest repeatability of organ uptake on PSMA-targeted F-DCFPyL PET/CT in patients with prostate cancer.

The Prostate

Authors: Rudolf A Werner, Susanne Lütje, Bilêl Habacha, Lena Bundschuh, Takahiro Higuchi, Andreas K Buck, Aleksander Kosmala, Constantin Lapa, Markus Essler, Martin A Lodge, Kenneth J Pienta, Mario A Eisenberger, Mark C Markowski, Michael A Gorin, Martin G Pomper, Steven P Rowe, Ralph A Bundschuh

OBJECTIVES: We evaluated F-DCFPyL test-retest repeatability of uptake in normal organs.

METHODS: Twenty-two prostate cancer (PC) patients underwent two F-DCFPyL PET scans within 7 days within a prospective clinical trial (NCT03793543). In both PET scans, uptake in normal organs (kidneys, spleen, liver, and salivary and lacrimal glands) was quantified. Repeatability was determined by using within-subject coefficient of variation (wCOV), with lower values indicating improved repeatability.

RESULTS: For SUV , repeatability was high for kidneys, spleen, liver, and parotid glands (wCOV, range: 9.0%-14.3%) and lower for lacrimal (23.9%) and submandibular glands (12.4%). For SUV , however, the lacrimal (14.4%) and submandibular glands (6.9%) achieved higher repeatability, while for large organs (kidneys, liver, spleen, and parotid glands), repeatability was low (range: 14.1%-45.2%).

CONCLUSION: We found acceptable repeatability of uptake on F-DCFPyL PET for normal organs, in particular for SUV in the liver or parotid glands. This may have implications for both PSMA-targeted imaging and treatment, as patient selection for radioligand therapy and standardized frameworks for scan interpretation (PROMISE, E-PSMA) rely on uptake in those reference organs.

© 2023 The Authors. The Prostate published by Wiley Periodicals LLC.

PMID: 37211963

Participating cluster members